4-氨基-2-甲基苯硼酸频那醇酯 | 631911-01-8

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸酯
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氨基-2-甲基苯硼酸频那醇酯
• 英文名称: 3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
• 英文别名: 3-methyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)phenylamine
• CAS: 631911-01-8
• 化学式: C₁₃H₂₀BNO₂
• mdl: MFCD08458198
• 分子量: 233.118
• InChiKey: ZZMUAVWNSFFTLI-UHFFFAOYSA-N

物化性质

• 沸点：
  356.4±35.0 °C(Predicted)
• 密度：
  1.03±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.58
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.538
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R22
• 海关编码：
  2934999090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  存储条件：2-8℃，避光、干燥且密封保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Amino-2-methylphenylboronic acid, pinacol ester
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Amino-2-methylphenylboronic acid, pinacol ester
CAS number: 631911-01-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H20BNO2
Molecular weight: 233.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氨基-2-甲基苯硼酸频那醇酯 在 四(三苯基膦)钯 吡啶 、 sodium carbonate 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.17h， 生成 N-(4-(5-cyano-4-methoxy-3-pyridinyl)-3-methylphenyl)methanesulfonamide
  参考文献：
  名称：

  [EN] SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS
  [FR] COMPOSÉS DE SULFONAMIDE UTILES EN TANT QU'INHIBITEURS DE CYP17

  摘要：

  公开的是化合物的磺胺类化合物的结构式（I）：或其立体异构体、N-氧化物、前药或其药学上可接受的盐，其中环A、R1、R2、R3、R4和R5在此处定义。还公开了使用这类化合物治疗与CYP17酶相关的疾病的方法，如癌症，并包括这类化合物的药物组合物。

  公开号：

  WO2012015723A1
• 作为产物：
  描述：

  4-硝基-2-甲苯胺 在 亚硝酸特丁酯 、 5%-palladium/activated carbon 、 2-(4-联苯基)-5-苯基唑 、 氢气 作用下， 以 甲醇 、 乙腈 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 8.0h， 生成 4-氨基-2-甲基苯硼酸频那醇酯
  参考文献：
  名称：

  Sandmeyer型转化合成三甲基锡烷基芳基硼酸酯化合物及其在化学选择性交叉偶联反应中的应用

  摘要：

  描述了一种基于Sandmeyer型反应的合成方法，可从硝基苯胺衍生物中获得锡和硼取代的芳烃。该转化可用于合成一系列官能化的三甲基锡烷基芳基硼酸酯。此外，还探索了Stille和Suzuki-Miyaura交叉偶联反应的化学选择性反应，并通过进行连续的一锅法式Stille和Suzuki-Miyaura交叉偶联反应合成了一系列m-和对-三苯基衍生物。

  DOI：

  10.1021/jo402618r

文献信息

• 一种小分子化合物
  申请人：嘉兴特科罗生物科技有限公司

  公开号：CN110627775A

  公开（公告）日：2019-12-31

  本发明提供的一种小分子化合物，其特征在于，为由如下分子通式所示的结构：其中，所述X1、X2选自碳或氮；所述G1为具有芳香性的碳环或杂环；所述G1环上的，任一或任几个氢原子为R1所取代；所述R1选自含氮基团。本发明的小分子化合物可作为高效和特异的JAK激酶抑制剂，特别是Tyk2抑制剂、和/或JAK1抑制剂、和/或JAK1/Tyk2或Tyk2/JAK1，Tyk2/Jak2双重抑制剂。
• Evaluation of functional groups as acetyl-lysine mimetics for BET bromodomain inhibition
  作者：Phillip P. Sharp、Jean-Marc Garnier、David C. S. Huang、Christopher J. Burns

  DOI：10.1039/c4md00182f

  日期：——

  This work provides new insights into a range of acetyl-lysine mimetics as BET bromodomain inhibitors.

  这项工作为BET溴结构域抑制剂中的一系列乙酰赖氨酸类似物提供了新的见解。
• Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US20040009995A1

  公开（公告）日：2004-01-15

  Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I 1 or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R 1 , R 2 , R 3 , R 4 and R 7 are defined in the specification, Z is SO or SO 2 , and Ar is an aromatic or heteroaromatic group as defined herein.

  揭示了一种治疗急性或慢性疾病症状的方法，该方法通过补体级联的经典途径介导，包括向需要此类治疗的哺乳动物施用公式I的化合物的治疗有效量或其溶剂化合物、水合物或药用可接受盐；其中在规范中定义了R1、R2、R3、R4和R7，Z为SO或SO2，Ar为本文中定义的芳香族或杂环芳基。
• NOVEL INHIBITORS OF HEPATITIS C VIRUS
  申请人：McKINNELL Robert Murray

  公开号：US20120114600A1

  公开（公告）日：2012-05-10

  The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

  该发明提供了以下式(I)的化合物： 其中变量在规范中定义，或其药用可接受盐，这些化合物是乙型肝炎病毒复制的抑制剂。该发明还提供了包括这些化合物的药物组合物，使用这些化合物治疗乙型肝炎病毒感染的方法，以及用于制备这些化合物的工艺和中间体。
• Discovery and characterization of bromodomain 2–specific inhibitors of BRDT
  作者：Zhifeng Yu、Angela F. Ku、Justin L. Anglin、Rajesh Sharma、Melek Nihan Ucisik、John C. Faver、Feng Li、Pranavanand Nyshadham、Nicholas Simmons、Kiran L. Sharma、Sureshbabu Nagarajan、Kevin Riehle、Gundeep Kaur、Banumathi Sankaran、Marta Storl-Desmond、Stephen S. Palmer、Damian W. Young、Choel Kim、Martin M. Matzuk

  DOI：10.1073/pnas.2021102118

  日期：2021.3.2

  There is no nonhormonal contraceptive pill for men, although hundreds of genes have been identified to play roles during spermatogenesis and fertilization in the male reproductive tract. To address the absence of contraceptive drugs for men, we established a DNA-encoded chemistry technology (DEC-Tec) platform. Our drug discovery campaign on BRDT, a validated spermatogenic-specific contraceptive target, yielded rapid discovery of potent and specific inhibitors of the second bromodomain of BRDT that have unique binding characteristics to BRDT-BD2 relative to BRDT-BD1. Our study emphasizes the robustness and validation of the DEC-Tec platform where the obtained structure–affinity relationship data would allow us to identify specific protein binders immediately without performing exhaustive medicinal chemistry optimization of compounds with potential as male contraceptives.

  尽管已经鉴定出数百个基因在男性生殖道的精子生成和受精过程中发挥作用，但目前还没有非激素类男性避孕药。为了解决男性避孕药的缺失问题，我们建立了一个DNA编码化学技术（DEC-Tec）平台。我们对BRDT（一个经过验证的特定于精子生成的避孕靶点）的药物发现工作，快速发现了BRDT第二个溴结构域的强效和特异性抑制剂，这些抑制剂与BRDT-BD1相比，对BRDT-BD2具有独特的结合特性。我们的研究强调了DEC-Tec平台的稳健性和验证性，所获得的结构-亲和力关系数据将使我们能够立即识别特定的蛋白结合剂，而无需对具有男性避孕药潜力的化合物进行详尽药物化学优化。